Ardelyx

Ardelyx, Inc. is a biopharmaceutical company. engages in the research, development and commercialization of medicine for the treatment of cardiorenal diseases. Its product portfolio includes tenapanor, which is an experimental medication that works exclusively in the gut and is in late-stage clinical development. The company was founded by Dominique Charmot, Peter G. Schultz, and Jean M. Frechet on October 17, 2007 and is headquartered in Fremont, CA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Ardelyx reports strong Q4 earnings, poised for product expansion

Ardelyx's Q4 performance reflects revenue growth, improved financial efficiency, and progress towards expanding its product portfolio.
While facing challenges such as regulatory processes and market competition, Ardelyx's strengths lie in successful product launches and a proactive commercial strategy.
Opportunities for Ardelyx include leveraging positive feedback for XPHOZAH, raising additional funds for growth, and diversifying revenue through new product launches.

Ardelyx reports sales growth, readies XPHOZAH launch amid challenges

Ardelyx showed strong sales growth for IBSRELA and is poised for the XPHOZAH launch
Financially, the company raised significant funds and maintains a healthy cash position
Challenges include managing expenses and improving profitability amidst losses
Opportunities lie in upcoming product launches and optimizing financial operations

Ardelyx reports strong Q2 performance amidst legislative challenges and growth opportunities

Ardelyx's Q2 performance reflects growth in IBSRELA sales and overall revenue, despite incurring a net loss.
The company faces challenges from pending legislation and financial burdens related to XPHOZAH launch preparation.
Opportunities lie in the potential of XPHOZAH launch, market reception of IBSRELA, and addressing legislative impacts.

Ardelyx reports strong Q3 earnings, poised for successful XPHOZAH launch

Ardelyx's Q3 performance reflects financial strength and positive market reception for IBSRELA.
Challenges in pricing strategy and market competition require strategic planning for XPHOZAH's launch.
Opportunities lie in leveraging financial stability, physician interest, and promotional activities for XPHOZAH success.
The company's commitment to patient access and learnings from IBSRELA will drive future growth and market penetration.

Ardelyx reports strong revenue growth driven by IBSRELA success

Ardelyx is strategically investing in growth, focusing on sustaining momentum for its products. The company is well-resourced and optimistic about the future performance of IBSRELA and XPHOZAH. Despite challenges in operating expenses, Ardelyx remains committed to its commercialization efforts.

Ardelyx reports robust Q1 performance driven by XPHOZAH success

Ardelyx's Q1 2024 earnings call showcased strong revenue growth, particularly driven by XPHOZAH and IBSRELA. The company's cash position remains healthy, and there is a clear focus on expanding market reach and driving adoption of key therapies.

Ardelyx reports robust Q2 earnings, focuses on patient access advocacy

Ardelyx's Q2 2024 performance reflects strong revenue growth driven by IBSRELA and XPHOZAH, with a focus on shareholder value and patient access advocacy. While facing challenges in legal battles and expense management, the company is poised to capitalize on opportunities through sales force expansion and market differentiation strategies.

Ardelyx (ARDX) reports robust Q3 earnings, navigates Medicare coverage challenges

Ardelyx's Q3 earnings call highlighted strong financial performance, success of key medications, and strategies to address Medicare coverage challenges. The company's focus on patient access, commitment to therapy availability, and positive market impact showcase its growth potential and resilience in the market.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Ardelyx, Inc. is a biopharmaceutical company, which engages in the business of developing and commercializing biopharmaceutical products. The firm is also involved in developing a unique and innovative platform that enables the discovery of new biological mechanisms and pathways to develop potent and efficacious therapies that minimize the side effects and drug-drug interactions frequently encountered with traditional, systemically absorbed medicines. The company was founded by Dominique Charmot, Peter G. Schultz, and Jean M. Frechet in October 2007 and is headquartered in Waltham, MA.

Continued successful launch of IBSRELA, with Q1 net product sales of $11.4 million XPHOZAH New Drug Application resubmitted on April 17, 2023 Company ends Q1 with over $130 million in cash and investments Conference call scheduled for 4:30 PM Eastern Time WALTHAM, Mass., May 03, 2023 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class medicines that meet significant unmet medical needs, today reported financial results for the first quarter ended March 31, 2023 and provided a business update.

Ardelyx Reports First Quarter 2023 Financial Results and Provides Business Update

WALTHAM, Mass., May 01, 2023 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class medicines that meet significant unmet medical needs, today announced that additional data supporting the efficacy and safety of IBSRELA will be presented in a poster at the 2023 Digestive Disease Week Conference (DDW 2023) to be held May 6-9, 2023, in Chicago, Illinois.

Ardelyx Announces Additional Data Supporting First-In-Class IBSRELA® (tenapanor) for Adults with IBS-C, to be Presented at the 2023 Digestive Disease Week Conference

WALTHAM, Mass., April 26, 2023 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class medicines that meet significant unmet medical needs, today announced it will hold a conference call on Wednesday, May 3, 2023, at 4:30 p.m.

Ardelyx to Report First Quarter 2023 Financial Results and Provide Business Update on May 3, 2023

Ardelyx: Underappreciated Biotech With Potential FDA Approval On Deck.

Ardelyx: Underappreciated Biotech With Potential FDA Approval On Deck

Altimmune

Cidara Therapeutics

FaZe Holdings Inc

ImmunityBio

Inovio Pharmaceuticals

Olaplex Holdings

RLX Technology

Silvergate Capital Corp

Tupperware

10 Penny stocks under $5 to watch right now The post Top Penny Stocks To Buy Now? 10 To Watch Under $5 appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

Top Penny Stocks To Buy Now? 10 To Watch Under $5

Three posters support the important role that XPHOZAH, a novel phosphate absorption inhibitor, could potentially play in the treatment of hyperphosphatemia

Ardelyx Presents Positive Data Further Supporting Efficacy and Safety of XPHOZAH® (tenapanor) at National Kidney Foundation 2023 Spring Clinical Meetings

B2Gold

Nuuve

As an investor, it is essential to have a diverse range of stocks within a portfolio. Penny stocks may not make up most of someone's holdings, but they are a crucial investment addition.

3 Penny Stocks to Add to Your Watchlist for Potential Breakouts

Penny stocks to watch before next week. The post 7 Top Penny Stocks Under $5; Time To Buy Now?

7 Top Penny Stocks Under $5; Time To Buy Now?

Cabaletta Bio

89bio Inc

iShares Genomics Immunology and Healthcare ETF

Meihua International Medical Technologies Co

Verona Pharma

Biotech is all over the 52-week high leaderboard

Is This the Most Lucrative Way to Play AI?

iBio

OPKO Health

Rigel Pharmaceuticals

4 biotech penny stocks to watch right now. The post 4 Top Penny Stocks To Watch With Big Biotech News This Quarter appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

4 Top Penny Stocks To Watch With Big Biotech News This Quarter

Ardelyx's sole marketed drug can't keep the company afloat by itself until it gets broader insurance coverage. The company is resubmitting a new drug application as early as next month.

Ardelyx Regulatory Catalyst Looms In April, But Invest In It Longer

No doubt about it — it's a great day to be invested in Ardelyx (NASDAQ: ARDX ) stock. Not only did the company just release expectation-beating fourth-quarter results, but an analyst group recently gave shares an upgrade and ambitious price target.

Why Is Ardelyx (ARDX) Stock Up 25% Today?

Akebia Therapeutics

Joby Aviation

Penny stocks insiders are selling? What the details suggest.

3 Penny Stocks Insiders Are Active In, Time To Buy Or Sell Now?

Ardelyx, Inc. (NASDAQ:ARDX ) Q4 2022 Earnings Conference Call March 2, 2023 4:30 PM ET Company Participants Caitlin Lowie - VP, Corporate Communications and IR Mike Raab - President and CEO Justin Renz - CFO Susan Rodriguez - CCO Rob Blanks - Chief Regulatory Affairs and Quality Assurance Officer Conference Call Participants Laura Chico - Wedbush Securities Yigal Nochomovitz - Citi Peyton Bohnsack - TD Cowen Operator Good afternoon everyone and welcome to the Ardelyx Fourth Quarter 2022 Conference Call. At this time, all participants are in a listen-only mode.

Ardelyx, Inc. (ARDX) Q4 2022 Earnings Call Transcript

Ardelyx (ARDX) delivered earnings and revenue surprises of 500% and 59.45%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

Ardelyx (ARDX) Surpasses Q4 Earnings and Revenue Estimates

Continued successful launch of IBSRELA, ending FY 2022 with $15.6 million in net product sales

Ardelyx Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update

WALTHAM, Mass., Feb. 27, 2023 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class medicines that meet significant unmet medical needs, today announced that Mike Raab, president and chief executive officer of Ardelyx, will participate in a GI/Microbiome panel discussion at the Cowen 43rd Annual Health Care Conference on Monday March 6, 2023 at 9:10 A.M. Eastern Time in Boston, MA.

Ardelyx to Participate at the Cowen 43rd Annual Health Care Conference

Here is how Ardelyx (ARDX) and Agile Therapeutics (AGRX) have performed compared to their sector so far this year.

Are Medical Stocks Lagging Ardelyx (ARDX) This Year?

Ardelyx (ARDX) is expected to report better-than-expected sales growth of its only marketed product, Ibsrela (tenapanor) and provide an update on the NDA resubmission timeline for Xphozah, tenapanor.

Ardelyx Inc. (ARDX) to Report Q4 Earnings: What's in Store?

Athenex

Personalis Inc

Use these tips for making money with penny stocks The post A Short Guide to Making Money With Penny Stocks in 2023  appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

A Short Guide to Making Money With Penny Stocks in 2023

Aligos Therapeutics

Apexigen Inc

Geron

Analysts have put these on their list of penny stocks to buy. Do you agree?

4 Penny Stocks To Buy According To Analysts & Targets Over 600%

Is Ardelyx (ARDX) Outperforming Other Medical Stocks This Year?

American Lithium Corp

Bit Digital, Inc

Lion Electric

Having gambled in under-the-radar penny stocks myself, I can tell you firsthand, the outcome hasn't always been great. There are a lot of risks involved, so tread lightly.

5 Under-the-Radar Penny Stocks With 100% Upside Potential

Amarin Corporation Plc

Oatly

3 penny stocks to watch this week. The post Penny Stocks To Buy In 2023?

Penny Stocks To Buy In 2023? 3 To Watch In January

Digital Brands Group Inc

NeuroBo Pharmaceuticals Inc

Silo Pharma Inc

Penny stocks to watch this week with news before 2023. The post Best Penny Stocks To Buy Before 2023?

News for Ardelyx Stock (ARDX)